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Abstract
Background: Protein assemblies named kinetochores bind sister chromatids to the mitotic spindle and orchestrate sister
chromatid segregation. Interference with kinetochore activity triggers a spindle checkpoint mediated arrest in mitosis,
which frequently ends in cell death. We set out to identify small compounds that inhibit kinetochore-microtubule binding
for use in kinetochore-spindle interaction studies and to develop them into novel anticancer drugs.
Methodology/Principal Findings: A fluorescence microscopy-based in vitro assay was developed to screen compound
libraries for molecules that prevented the binding of a recombinant human Ndc80 kinetochore complex to taxol-stabilized
microtubules. An active compound was identified that acted at the microtubule level. More specifically, by localizing to the
colchicine-binding site in ab-tubulin the hit compound prevented the Ndc80 complex from binding to the microtubule
surface. Next, structure-activity analyses distinguished active regions in the compound and led to the identification of highly
potent analogs that killed cancer cells with an efficacy equaling that of established spindle drugs.
Conclusions/Significance: The compound identified in our screen and its subsequently identified analogs represent new
antitubulin chemotypes that can be synthetically developed into a novel class of antimitotic spindle drugs. In addition, they
are stereochemically unique as their R- and S-isomers mimic binding of colchicine and podophyllotoxin, respectively, two
antitubulin drugs that interact differently with the tubulin interface. Model-driven manipulation of our compounds
promises to advance insight into how antitubulin drugs act upon tubulin. These advances in turn may lead to tailor-made
colchicine site agents which would be valuable new assets to fight a variety of tumors, including those that have become
resistant to the (antispindle) drugs used today.
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Introduction
Many anticancer drugs used in the clinic inhibit cell division as
tumors are characterized by uncontrolled proliferation [1]. Cell
division is the process during which a mother cell generates two
genetically identical daughter cells. In S phase, maternal chromo-
somes replicate and form sister chromatid pairs. During the
subsequent M phase, protein assemblies called kinetochores form
on the centromere of each chromatid and attach the sister
chromatids in a bipolar manner to the microtubules (MTs) of the
mitotic spindle. The spindle MTs are a dynamic array of ab-tubulin
fibers that extend from two oppositely localized centrosomes. At the
metaphase-anaphase transition, the sister chromatids are first
separated and then segregated into the daughter cells. During the
final cell cycle stage named cytokinesis, the daughters divide, each
containing an identical set of chromosomes [2].
Antiproliferative drugs used in the clinic include agents that
target mitotic spindle integrity or dynamics [3]. In response to the
spindle defects caused by these drugs, the spindle assembly
checkpoint (SAC) delays mitosis allowing cells to reverse the drug-
induced damage [4]. Cells that do not recover and satisfy the SAC
either undergo cell death (apoptosis) or adapt. Adapting cells may
continue to cycle, undergo senescence or die in the subsequent
interphase [5]. Almost all antispindle drugs suppress MT integrity
and dynamics by stabilizing MTs and stimulating tubulin
polymerization, or by destabilizing MTs and inhibiting tubulin
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ixabepilone, or MT destabilizing agents including vinca alkaloids
and estramustine, are very effective against a broad range of
tumors [3]. However, resistance to antitubulin drugs has become a
significant problem due to P-glycoprotein overexpression and,
perhaps, to mutations in genes encoding the tubulin subunits,
changes in tubulin isotype composition of MTs, altered expression
or binding of MT-regulatory proteins including Tau, mutations in
or reduced levels of c-actin, and/or a reduced apoptotic response
[3,6]. To deal with resistance, structurally diverse antiMT drugs
are being developed while alternative mitosis-specific drug targets
are being evaluated [7,8].
A mitosis-specific structure that has recently been focused on for
development into a drug target is the kinetochore, the protein
complex that coordinates chromosome segregation. Interfering
with kinetochore activities, including MT binding, triggers a SAC-
mediated arrest of mitosis, which frequently leads to cell death [9].
As kinetochores assemble from .100 proteins, they are, in
principle, almost inexhaustible drug targets.
We wished to identify compounds that inhibit kinetochore-MT
binding to develop them into new antimitotic agents. We also
wanted to use these compounds as chemobiological tools to study
the mechanisms that drive kinetochore-MT binding. To identify
such compounds we focused on the outer kinetochore Ndc80
complex, which attaches the kinetochore structure to the MTs of
the mitotic spindle [10]. To screen chemical libraries for active
molecules we developed an in vitro fluorescence microscopy-based
binding assay using a recombinant Ndc80 complex and taxol-
stabilized MTs. Of 10,200 compounds screened, one compound
prevented the Ndc80 complex from binding to the MTs by acting
at the MT level. More specifically, the compound localized to the
colchicine-binding site at the ab-tubulin interface. Using a
computational approach, the antitubulin compound was structur-
ally dissected and analogs were identified containing a 20-fold
higher antitubulin activity. Of these, the most potent compound
mitotically arrested and killed adenocarcinoma cells with an IC50
value of 25 nmol/l.
The classic colchicine site agents (e.g. colchicines, combretasta-
tins, podophyllotoxin), most of which are structurally similar and
rather complex in nature, are not used in the clinic because they are
systemically toxic. This is unfortunate as colchicine site agents
would represent powerful alternatives to the clinically used taxane-
or vinca-site drugs against which tumor cells have been developing
resistance. Structurally novel or less complicated colchicine site
compounds may be the answer to the problem of toxicity, as
illustrated by the highly potent stilbene colchicine derivatives, which
exhibit minimal toxicity [11]. The antitubulin hit compound and
lead analogs identified in this study are chemotypically unique
colchicine site agents. In addition, they interact with the colchicine-
binding pocket in a unique manner: our docking studies suggest that
the R-isomers interact with tubulin via their furan ring, while the
S-isomers localize to the colchicine pocket via their ester side chain.
Future analysis and modification of our compounds will advance
insight intothe colchicine site-drug interactionand promise to result
in new anticancer compounds with optimal performance and,
possibly, minimal toxicity.
Results
Microscopy-based in vitro screen for compounds that
prevent binding of the Ndc80 kinetochore complex to
MTs
To screen compound libraries for molecules inhibiting binding
of the outer kinetochore Ndc80 complex (Ndc80, Nuf2, Spc24,
Spc25) to MTs, we used a fluorescence microscopy-based in vitro
approach (Fig. 1). First, the recombinant human Ndc80 construct,
used to crystallize the complex [12], was produced in Escherichia coli
using a bicistronic plasmid from which the Nuf2-Spc24 and
Ndc80-Spc25 peptides were generated (Fig. 1A). Following their
intracellular assembly, the complex was purified from E. coli cell
extract based on the GST tag at the N-terminus of Nuf2. The
complex was released in solution with PreScission Protease (its
recognition sequence was introduced between the GST tag and
the NUF2 coding sequence) and was separated from contaminants
by gel filtration chromatography (Fig. 1A). The high degree of
purity of the preparation was confirmed by SDS-PAGE analysis
and coomassie staining, which identified only both peptides
(Fig. 1B). Next, the Ndc80 complex was fluorescently labeled with
the Alexa Fluor 488 C5-maleimide (next named the Ndc80
488
complex) and was separated from unreacted fluorophore by gel
filtration chromatography. The final preparation was highly pure
as evidenced by gel filtration analysis and detection at 519 nm
(emission maximum of the Alexa Fluor 488 dye) and at 280 nm
(intrinsic protein fluorescence) (Fig. 1B). Next, the Ndc80
488
complex (0.1 mmol/l) was incubated with 10,200 compounds
(comprising the Chembridge DIVERset and a compound
collection from the Univ. Rome) at a starting concentration of
50 mmol/l. Binding (or lack thereof) of the complex to rhodamine-
labeled taxol-stabilized MTs (0.1 mmol/l) was scored by wide-field
fluorescence microscopy (Fig. 1C; images in Fig. 2A). One
compound, named ‘‘compound B’’ (6-furan-2-yl-3-methyl-4-oxo-
4,5,6,7,-tetrahydro-1H-indole-2-carboxylic acid tetrahydro-furan-
2-ylmethyl ester; DIVERset, Chembridge) was found to be active
(Fig. 2A,B). Total internal reflection fluorescence microscopy was
used to establish the IC50 value of the compound, which was
measured to be ,20 mmol/l (Fig. 2C).
Functional evaluation of the inhibition of Ndc80
488
complex-MT binding by compound B
A compound inhibiting the Ndc80
488 complex-MT interaction
could act either against the complex or against the MTs. To probe
the specificity of compound B toward the Ndc80
488 complex, we
examined its ability to inhibit MT binding of recombinant CLIP-
170
488, a MT plus-end tracking protein. We found that compound
B prevented CLIP-170
488 from binding to MTs (Fig. 2D),
suggesting that compound B acted at the MT level. Of note,
MT poison nocodazole did not prevent the Ndc80
488 complex
from binding to the taxol-stabilized MTs (Fig. 2E), suggesting that
compound B interacted in a unique manner with the stabilized
MT polymer, and indirectly, with binding of the Ndc80
488
complex to the MTs.
To study whether compound B affected mitosis, HeLa cells
were synchronously released from G1/S (thymidine block) into
growth media containing 0.1–50 mmol/l compound B. Time-lapse
videomicroscopy showed an accumulation of mitotic cells in the
presence of the compound, while the mock-treated cells progressed
through mitosis (Fig. 3A, upper and lower panels). At compound B
concentrations of 5 mmol/l and above, the cells arrested robustly
in metaphase (,15 h) and then underwent cell death, as diagnosed
by cell shrinkage (Fig. 3B). The observed mitotic delay came from
mitotic checkpoint activity as confocal immunofluorescence (IF)
imaging showed that SAC protein Mad1 accumulated at
kinetochores in cells treated with compound B (as with
nocodazole, which was used as a positive control, Fig. 3C). The
IF analysis further revealed that sister chromatids (DAPI) and
kinetochores (CREST serum) were not aligned on the metaphase
plate. This phenotype is indicative of chromatids being unable to
bind to spindle MTs and/or of spindle defects, as observed with
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kinetochore-spindle attachment or interfered with spindle integri-
ty, we examined by confocal IF imaging the localization of
chromosomes and kinetochores, and the state of the spindle (anti-
a-tubulin) in cells synchronously released from a G1/S arrest into
medium containing 10 mmol/l of compound B. All cells lacked a
mitotic spindle, as with nocodazole (Fig. 3D), supporting the idea
that compound B acts at the MT level, probably by inhibiting
tubulin assembly. Because drugs that inhibit tubulin polymeriza-
tion also destabilize MTs [3], we next probed whether compound
B destabilized metaphase spindles. We arrested HeLa cells in
metaphase using 10 mmol/l of proteosome inhibitor MG132. The
cells, all of which contained a mitotic spindle, were then treated
with 1% DMSO or 10 mmol/l compound B. IF imaging showed
that compound B depolymerized the spindle (Fig. 3D, bottom set of
panels). Thus, compound B prevents tubulin assembly and
destabilizes spindle MTs in cells.
To probe whether the activity of compound B is reversible or
not, we synchronously released G1/S arrested HeLa cells into
fresh medium containing 5 mmol/l compound B (nocodazole was
used as the positive control). The cells efficiently arrested in
metaphase due to absence of a mitotic spindle (Fig. 3E, left column of
images in each set). Compound B and nocodazole were then washed
out and the cells were released in MG132 containing medium.
Within 3 h, all cells had arrested with a mitotic spindle suggesting
that our compound does not covalently bind to tubulin, allowing
for full reversibility of its intracellular activity (Fig. 3E, right column
of images in each set).
Taxol inhibits the MT-depolymerization activity of
compound B
During our screen we found MTs to be stable in the presence of
compound B (Fig. 2, panel A and panels C to E), suggesting that taxol
prevented MT depolymerization by the compound. To test this
hypothesis, we treated HeLa cells with 0.5 mmol/l taxol, thereby
arresting them in metaphase with stabilized spindles. Following the
addition of either 10 mmol/l compound B or 1% DMSO, the
spindles did not depolymerize (Fig. 4A). Hence, the effects of taxol
are likely dominant over those of compound B since our previous
experiments had shown that compound B alone efficiently
depolymerized metaphase spindles at 10 mmol/l (Fig. 3, panels C
and D). To quantify the taxol-mediated inhibition of MT
disassembly by compound B, we measured in vitro the depolymer-
ization of taxol (20 mmol/l)-stabilized MTs following incubation
with 50 mmol/l compound B (the screen condition). Nocodazole
and maytansine (both at 50 mmol/l) were included as controls. At
50 mmol/l, compound B depolymerized 3% of the taxol-stabilized
MT population, while nocodazole and maytansine depolymerized
11% and 31% of the taxol-treated MTs, respectively (Fig. 4B). The
limited ability of compound B to depolymerize taxol-stabilized
MTs explains why we did not identify compound B as a MT-
depolymerizing drug in our screen. This finding further supports
our hypothesis that the interaction of compound B with the
stabilized MTs must have prevented the Ndc80
488 complex from
establishing contact with the MT surface.
Compound B is a colchicine site effector of MT assembly
and stability
To quantify the antitubulin activity of compound B, we added 1–
50 mmol/l compound B to 10 mmol/l ab-tubulin. Tubulin
polymerization in GTP-containing buffer was tracked turbidimet-
rically at 350 nm [13,14], with combretastatin A-4 and nocodazole
acting as controls. Compound B inhibited tubulin polymerization
with an IC50 value of 5.5 mmol/l, whereas combretastatin A-4 and
nocodazole were 5-fold more effective (IC50 values of 1.2 mmol/l
and 0.96 mmol/l, respectively; Fig. 5A). Because compound B also
destabilized spindle MTs in cells (Fig. 3D), we also quantified in vitro
the MT depolymerization activity of the compound. For this
purpose, MTs were assembled from 10 mmol/l ab-tubulin; 5 min
into the reaction compound B was added in concentrations up to
200 mmol/l. MT depolymerization was tracked as a decrease in
turbidity at 350 nm (Fig. 5B). Compound B affected MT stability
only at molar ratios exceeding 20:1, while nocodazole induced MT
depolymerization at a drug:tubulin ratio of 1 (Fig. 5B). Thus,
compound B inhibited tubulin polymerization at a concentration at
least 40-fold lower than that needed to disassemble MTs. In
contrast, a 10-fold difference was observed for nocodazole (Fig. 5B
versus Fig. 5A). The measured discrepancies in the antitubulin
activities of compound B are typical for tubulin destabilizing
drugs [3].
Agents that inhibit tubulin polymerization and destabilize MTs
include the colchicinoids, combretastatins, benzimidazole carba-
mates, vinca alkaloids, and maytansinoids [3]. These drugs act
primarily at b-tubulin in the ab-heterodimer, albeit at different
sites. Colchicinoids, combretastatins and benzimidazole carba-
mates (e.g. nocodazole) localize to the colchicine site near the C-
terminus of b-tubulin at the ab-tubulin intradimer interface
[15,16], whereas vinca alkaloids and maytansinoids localize to the
N-terminal GTPase domain of b-tubulin [17,18]. To determine
whether compound B (1–50 mmol/l) acts at the colchicine-binding
site, we assayed whether it inhibited binding of [
3H]colchicine
(5 mmol/l) to tubulin (1 mmol/l), in comparison with combretas-
tatin A-4 and nocodazole (Fig. 5C). Compound B significantly
inhibited [
3H]colchicine binding to tubulin, indicating that it acts
at the colchicine site. Its binding affinity, however, was ,3-fold
lower than that of nocodazole (compare values at 5 mmol/l and
20 mmol/l, Fig. 5C).
Structure-activity analysis of compound B leads to the
identification of furan-metoticas
Compound B (Fig. 2B) represents a novel antitubulin chemo-
type. Consequently, its overt lack of structural similarity with
known colchicine site agents made it difficult to understand which
part of compound B was responsible for its antitubulin activity. To
solve this problem, we performed a computer-assisted search of
commercial libraries comprising ,3,000,000 compounds for
molecules containing either a 6-furan-2-yl-3-methyl-4-oxo-
4,5,6,7-tetrahydro-1H-indole structure (encircled in blue, Fig. S1)
or the C2 carboxylate-based tetrahydrofurfuryl side group
(encircled in red, Fig. S1). We identified 104 compounds
containing a tetrahydrofurfuryl group; none were active in the
Figure 1. Screen for compounds inhibiting binding of the recombinant Ndc80 kinetochore complex to taxol-stabilized
microtubules. Schematic of the expression, purification and fluorescent labeling of the recombinant human Ndc80 kinetochore complex
(Ndc80
488 complex) used in the screen (A). Recombinant Ndc80 complex obtained by GST-based purification and PreScission Protease-mediated
release from the affinity beads (left panel). Gel filtration profile (Superdex 200) of the Ndc80
488 complex obtained by labeling the purified complex
with Alexa Fluor 488 C5-maleimide fluorophore (right panel) (B). Schematic of the fluorescence microscopy-based screen for compounds inhibiting
the binding of the Ndc80
488 complex (green) to rhodamine (red) labeled, taxol-stabilized MTs (tubulin subunits are colored black and grey) (C).
doi:10.1371/journal.pone.0011603.g001
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488 complex-MT binding assay. In contrast, 17 compounds
containing the 6-furan-2-yl-3-methyl-4-oxo-4,5,6,7-tetrahydro-
1H-indole fragment inhibited to varying extent the binding of
the Ndc80
488 complex to MTs, suggesting that this region harbors
the antitubulin activity of compound B. Four of the 17 compounds
(named A6, D7, E7, and A8) were ,20-fold more active than
compound B, as measured in the Ndc80
488 complex-MT binding
assay (IC50 values of ,1 mmol/l; Fig. 6A). Their enhanced activity
was also confirmed turbidimetrically: the IC50 values of com-
pounds A6, D7, E7 and A8 for inhibiting tubulin assembly were
2.3, 3.0, 4.0, and 4.2-fold lower, respectively, than that of
compound B. The activity of the most potent molecule, A8, was
similar to that of combretastatin A-4 and nocodazole (Fig. 6B).
The capacity of these four molecules to destabilize MTs in vitro was
also superior to that of compound B; the ability of compound A8
to depolymerize MTs was 12-fold higher than that of compound B
and was 10% higher than that of nocodazole (Fig. 6C). The high
antitubulin activity of compounds D7, A6, A8 and E7 likely results
from an improved ability of the compounds to localize to the
colchicine site. Indeed, compounds D7, A6, A8 and E7 were 3-fold
more active than compound B as inhibitors of [
3H]colchicine-
tubulin binding (Fig. 6D), concordant with their inhibitory effects
on tubulin assembly (Fig. 6B).
Next, we determined whether the elevated antitubulin activities
of compounds A6, A8, D7 and E7 (versus compound B), and the
discrepancies in activity between the compounds themselves were
reflected in their effects on mitosis. G1/S synchronized HeLa cells
were released into growth medium containing 100 or 500 nmol/l
of these compounds or compound B; the duration of the mitotic
delay by the compounds and the percentage of cells undergoing
subsequent cell death were scored. Except for A6, the new
compounds were also more active than compound B in this cell-
based assay (Fig. 6E). Possibly, compound A6, which has a bulky
side group similar to that of compound B (Fig. 6A) has a reduced
uptake or lower affinity for the colchicine site in cells. The four
compounds triggered mitotic delays to an extent that directly
reflects their activities in vitro (compare Fig. 6E and Fig. 6, panels B
to D). The observation that the compounds caused mitotic delays
of varying duration also suggests that their side chains are
important for their biological activity and are unlikely to be
hydrolyzed in human cells. At 500 nmol/l, the most potent
molecules (D7, E7, and A8) elicited a robust mitotic block,
followed by cell death (Fig. 6E). Of note, each of our compounds
acted in cells with an efficacy exceeding those measured in vitro
(compare Fig. 6E and Fig. 5). This discrepancy may be due to
increased compound:tubulin ratios in cells. Alternatively, the
compounds may be modified intracellularly, resulting in enhanced
activity. Because compound B and the four second-generation
compounds are 6-furan-2-yl-3-methyl-4-oxo-4,5,6,7-tetrahydro-
1H-indole-2-carboxylic acid derivatives, we have named these
tubulin inhibitors ‘‘furan-metoticas’’.
Antiproliferation activity of furan-metoticas
After confirming that our most active compound A8, inhibited
spindle formation, depolymerized metaphase spindles, acted in a
reversible manner, and triggered a mitotic arrest and death of
HeLa cells (Fig. 7), we examined the efficacy of the compound on
the growth of the A2780 (ovarian carcinoma) and HCT-116
(colorectal carcinoma) tumor cell lines. RPE, a telomerase-
immortalized cell line derived from retinal pigment epithelium,
served as the non-cancer control. Antitubulin agents colchicine
and nocodazole were used as controls for drug activity. The RPE,
A2780, and HCT-116 cells were efficiently killed by compound A8
and the control drugs. Importantly, the efficacy of compound A8
(IC50: 25 nmol/l) was similar to that of the established tubulin
inhibitors (Fig. 8).
Discussion
During the last twenty-five years antispindle drugs have been
used with great success in the fight against cancer. However, as
cancer cells are developing resistance against these drugs, there is
an urgent need for compounds targeting alternative mitotic
targets. As kinetochores orchestrate chromosome segregation
and comprise .100 proteins, they are appealing mitosis-specific
drug targets. The high antitumor activity of compounds inhibiting
kinetochore regulators (Aurora kinase, PLK1) and the kineto-
chore-associated kinesin CENP-E supports the concept of
targeting kinetochore function to eradicate proliferating cells
[7,9,19]. The complexity of kinetochores, the lack of insight into
intrakinetochore protein-protein contacts and protein-activity
relationships, as well as the difficulty to produce kinetochore
subunits in large quantities for use in in vitro screens has long
hampered the conversion of structural kinetochore components
into anticancer drug targets. Arguably the most intensely studied
kinetochore subunit, both from a functional and structural point of
view, is the outer kinetochore Ndc80 complex, which recruits the
SAC and attaches the kinetochore structure to the MTs of the
mitotic spindle [10,12]. As the Ndc80 complex can be produced
recombinantly in high quantity and because the recombinant
complex is fully active as shown following injection in cells [12] we
focused on this complex to screen for inhibitors of kinetochore-
MT binding. Such inhibitors would leave sister chromatids
detached from the spindle, leading to a robust SAC mediated
arrest of the cells in mitosis. As mitotically arrested cells frequently
undergo apoptotic death these drug would be potent eradicators of
cancer cells characterized by uncurbed proliferation. In addition,
we’d like to use these inhibitors to study how detached
kinetochores prepare for kinetochore-spindle contact. Out of the
10,200 compounds that were screened, one molecule (compound
B; 6-furan-2-yl-3-methyl-4-oxo-4,5,6,7,-tetrahydro-1H-indole-2-
carboxylic acid tetrahydro-furan-2-ylmethyl ester) prevented
binding of the Ndc80 complex to taxol-stabilized MTs by acting
at the MT level. Indeed, the compound prevented MT binding
not only of the Ndc80 complex but also of the MT plus-end
tracking CLIP-170 protein, suggesting that it acted specifically
towards the MTs. We confirmed this hypothesis and showed that
the compound localized to the colchicine site at the ab-tubulin
interface. We believe that a conformational change in the MT
polymers caused by binding of compound B to the colchicine
pocket in the ab-tubulin dimer may have prevented the
Figure 2. Compound B prevents the recombinant Ndc80 kinetochore complex from binding to taxol-stabilized microtubules. Effect
of compound B (50 mmol/l) on binding of the Ndc80
488 complex to rhodamine-labeled, taxol-stabilized MTs as assayed using inverted wide-field
fluorescence microscopy. The scale bar represents 4 mm( A). Structure of compound B; 6-furan-2-yl-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-2-
carboxylic acid (tetrahydro-furan-2-yl)methyl ester (B). Measurement of the IC50 value of compound B using total internal reflection fluorescence
microscopy. The scale bar represents 4 mm( C). Compound B (50 mmol/l) prevented MT-associating protein CLIP-170
488, used as a specificity control,
from binding to taxol-stabilized MTs. The scale bar represents 4 mm( D). Antitubulin control drug nocodazole (50 mmol/l) did not prevent the
Ndc80
488 complex from binding to MTs. The scale bar represents 4 mm( E).
doi:10.1371/journal.pone.0011603.g002
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colchicine-site agent nocodazole did not prevent the Ndc80
complex from binding to taxol-stabilized MTs, further arguing
that compound B affects MT integrity in a unique manner. Of
note, our screen also identified a second compound (4-5-2-1H-
benzimidazol-2-yl-2-cyano-vinyl-furan-2-yl-benzoic acid), which
specifically targeted the Ndc80 complex as it did not inhibit the
MT binding of CLIP-170 nor of fluorescently labeled anti-tubulin
antibodies (data not shown). The identification of this compound
further validates the potency of our screen. Unfortunately, our
study of the interaction between compound C and the Ndc80
complex has been complicated by the inability of the compound to
enter cells. However, injecting the compound into HeLa cells
significantly reduced the ability of the cells to align their sister
chromatids to the metaphase plate, consistent with impaired
kinetochore-spindle binding (De Wulf P. and DeLuca J.G.,
preliminary observations). We are currently manipulating the
compound to make it cell permeable and are testing a battery of
Figure 3. Compound B inhibits tubulin assembly and destabilizes spindles, resulting in mitotic block and cell death. Live-cell imaging
of HeLa cells synchronized in G1/S and released into medium containing compound B (50 mmol/l) or mock solution (1% DMSO). The scale bar
represents 20 mm. The plot shows the mitotic index of the cultures over time (compound B, red bars; mock [1% DMSO], green bars) (A). Compound B
induced a mitotic delay (1–10 mmol/l) and cell death (5–10 mmol/l) (B). The mitotic delay triggered by compound B (10 mmol/l) resulted from mitotic
checkpoint activity as indicated by the presence of SAC protein Mad1 at kinetochores. Nocodazole (0.5 mmol/l) acted as a positive control. The scale
bar represents 10 mm( C). Compound B inhibited spindle formation (row 2) and destabilized metaphase spindles (row 5) in HeLa cells. Nocodazole
(0.5 mmol/l) acted as the positive control. The scale bar represents 10 mm( D). The antitubulin activity of compound B on human cells is reversible as
the cells formed a mitotic spindle structure when the drug was washed out and the cells were released into fresh medium containing 10 mmol/l
MG132. Nocodazole (0.5 mmol/l) acted as the positive control. The scale bar represents 10 mm( E).
doi:10.1371/journal.pone.0011603.g003
Figure 4. Taxol inhibits the microtubule-destabilizing activity of compound B. Taxol (0.5 mmol/l) prevented spindle depolymerization by
compound B (10 mmol/l) when both were added to HeLa cells arrested in metaphase with proteosome inhibitor MG132. The scale bar represents
10 mm( A). Depolymerization by compound B, nocodazole, and maytansine (50 mmol/l each) of taxol-stabilized MTs in vitro. The bars represent
standard errors (B).
doi:10.1371/journal.pone.0011603.g004
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complex, both in vitro and in cells.
Computer-assisted SAR analysis of compound B revealed that
its furan-associated bicyclic nucleus harbors the antitubulin
activity of the compound whereas its C2 side chain is important
for overall activity, possibly by affecting the localization of the
compound to the tubulin pocket. These analyses also led to the
identification of compound analogs 20-fold more potent than
compound B. Preliminary docking of the R- and S-enantiomers of
compound B and its analogs onto the X-ray structures of N-
deacetyl-N-(2-mercaptoacetyl)-colchicine and podophyllotoxin
bound to tubulin [15,16] revealed that the bulky C2-linked
tetrahydrofuran and cyclohexane groups in compounds B and A6
may result in unfavorable ligand-protein and intra-ligand contacts,
Figure 5. Compound B inhibits tubulin assembly and destabilizes MTs by acting at the tubulin colchicine site. Compound B inhibited
tubulin assembly in vitro; combretastatin A-4 and nocodazole acted as positive controls (A). Compound B depolymerized non-stabilized MTs in vitro;
nocodazole acted as the positive control (B). Compound B competed with [
3H]colchicine for binding to the colchicine site in ab-tubulin. The bars
represent standard deviations (C).
doi:10.1371/journal.pone.0011603.g005
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both in vitro and in cells. The analyses further showed that the
stereoelectronic features of the R-enantiomers closely resemble
those of colchicine, while the stereoelectronic properties of the S-
enantiomers resemble those of colchicine-site drug podophyllo-
toxin. The R-enantiomers appear to interact with the tubulin
colchicine pocket via their furan ring, while the S-enantiomers
seem to localize to tubulin via their C2 side chains. To the best of
our knowledge no other class of antitubulin compounds behaves in
such a stereochemically unique manner. Separation of the
compound isomers is in progress to determine whether the R-
and S-forms show a different level of activity toward tubulin in vitro
and in cells.
The most active of our colchicine site compounds kills tumor
cells with an IC50 value of 25 nmol/l, a potency similar to that of
spindle drugs used in the clinic. In vivo analyses will be performed
to confirm efficacy in xenograft mouse models. So far colchicine
site effectors (e.g. colchicinoids, combretastatins) have not been
used in the clinic as they cause systemic toxicity. The classic
colchicine site drugs are large, complex molecules that share a
high level of structural similarity, e.g. most carry a tubulin-
interacting trimetoxyphenyl group. However, novel colchicine site
effectors that are structurally simple or chemotypically diverse may
be the answer to the acute toxicity issues as illustrated by the
stilbene colchicine derivatives, which are highly potent but
minimally toxic agents [11]. Our antitubulin compounds represent
a chemotypically unique set of colchicines site agents (e.g. they do
not contain a trimetoxyphenyl group) and are some of the simplest
antitubulin compounds reported to date, both in the scientific and
patent literature. Their configuration and unique mode of
stereoselective interaction with tubulin will allow for a better
understanding of how antitubulin drugs work and will permit the
model-driven chemosynthetic generation of derivatives with
optimal activity and stability. Potent, non-toxic colchicine site
analogs would represent much needed tools to battle cancer cells
resistant to the currently used antispindle drugs.
Materials and Methods
Production of recombinant Ndc80
488 kinetochore
complex
Recombinant human Ndc80 complex (Ndc80
Bonsai complex)
was produced in Escherichia coli using a bicistronic expression
plasmid (Fig. 1A, [12]). Following transcription from the TAC
promoter/operator by induction with 0.4 mmol/l IPTG (20uC,
15 h), GST-Nuf2-Spc24 and Ndc80-Spc25 polypeptides were
Figure 6. Furan-metoticas inhibit tubulin assembly and destabilize microtubules. Structures of furan-metoticas B, A6, D7, E7, and A8, and
their IC50 values measured in the Ndc80
488-MT binding assay (A). Compounds A6, D7, E7 and A8 inhibited tubulin polymerization in vitro with an
efficiency exceeding that of compound B; combretastatin A-4 and nocodazole acted as positive controls. The bars represent standard deviations (B).
Compounds A6, D7, E7 and A8 efficiently depolymerized non-stabilized MTs in vitro; nocodazole acted as a positive control (C). Compounds B, A6, D7,
E7 and A8 competed with [
3H]colchicine for binding to tubulin; combretastatin A-4 acted as the positive control. The bars represent standard
deviations (D). Furan-metoticas triggered a mitotic block and subsequent cell death with high efficiency in HeLa cells (cervical adenocarcinoma). The
bars represent standard deviations (E).
doi:10.1371/journal.pone.0011603.g006
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PLoS ONE | www.plosone.org 11 July 2010 | Volume 5 | Issue 7 | e11603generated, which dimerized intracellulary into the GST-Ndc80
complex. The complex was isolated from E. coli cell extract
following incubation with glutathione beads. The complex was
released from the beads with PreScission Protease (GE Healthcare
Life Sciences) and contaminants were removed by gel filtration
chromatography (Superdex 200, GE Healthcare Life Sciences).
On average 4 mg of Ndc80 complex were obtained from 1 liter of
cell culture. Next, 1 mg Ndc80 complex was labeled with 0.1 mg
Alexa Fluor 488 C5-maleimide fluorophore (Invitrogen) at a 1.5-2
stoichiometry. The fluorescent complex (Ndc80
488 complex) was
separated from unreacted fluorophore by gel filtration chroma-
tography (Fig. 1B) and was then used to screen for compounds
inhibiting Ndc80
488 complex-MT binding (Fig. 1C). The
Ndc80
488 complex is fully functional as it is recruited to and acts
at kinetochores when injected into prometaphase HeLa cells [12].
Screening for compounds that prevent binding of the
Ndc80
488 complex to MTs
MTs were polymerized (30 min, 37uC) from a 1:10 mixture of
rhodamine-labeled:unlabeled bovine brain ab-tubulin (Cytoskele-
ton) in BRB-80 buffer (80 mmol/l PIPES pH 6.8, 1 mmol/l
MgCl2, 1 mmol/l EGTA) and were then stabilized with 20 mmol/l
taxol. The Ndc80
488 complex (0.1 mmol/l) was incubated with
100 mmol/l compound (30 min, 24uC) in 96-well polypropylene
plates (Eppendorf). The 10,000 compound DIVERset library
(Chembridge) and 200 compounds from the Department of
Medicinal Chemistry and Technologies, University of Rome La
Sapienza were used in the screen. Next, the MTs (100 nmol/l) were
added to the compound-Ndc80
488 complex solution in a 1:1 v/v
ratio. After incubation (10 min, 24uC), the reaction mixtures were
transferred to 96-well glass-bottom plates (Greiner Bio-one). Each
well was imaged at 519 nm and 590 nm with an IX81 Olympus
inverted wide-field microscope (Olympus). Total internal reflection
fluorescence imaging was performed with an Olympus IX71
inverted wide-field microscope (Olympus). ImageJ was used for
image processing (NIH, USA).
Tubulin polymerization and MT stability analysis
Polymerization of 10 mmol/l ab-tubulin in BRB-80 buffer was
monitored turbidimetrically at 350 nm for 15 min in a temper-
ature-controlled spectrophotometer (37uC; SpectraMax Plus
384,
Molecular Devices). To probe the effect of a compound on MT
stability the molecule was added 5 min after initiation of tubulin
assembly. The decrease in protein turbidity (350 nm) resulting
Figure 7. Compound A8 inhibits tubulin assembly and destabilizes spindle microtubules in HeLa cells and in vitro. Live-cell
videomicroscopy of HeLa cells treated with mock solution (1% DMSO) or with compound A8 (0.5 mmol/l) following release from synchronization in
G1/S (upper panel). The scale bar represents 20 mm. The plot shows the mitotic index of the cell cultures over time (compound A8, red bars; mock
[1% DMSO], green bars) (A). Compound A8 inhibited spindle formation (a-tubulin) in HeLa cells characterized by detached sister chromatids (DAPI/
CREST staining), as shown by confocal IF microscopy; nocodazole acted as a positive control. The antitubulin activity of compound A8 on human cells
is reversible as the cells formed a mitotic spindle structure when the drug was washed out and the cells were released into fresh medium containing
10 mmol/l MG132. The scale bar represents 10 mm( B). Compound A8 inhibited tubulin assembly (upper panel) and triggered MT depolymerization in
vitro (lower panel) (C). Compound A8 (50 mmol/l) mildly depolymerized taxol-stabilized MTs in vitro; nocodazole and maytansine (50 mmol/l) acted as
positive controls. The bars represent standard errors (D).
doi:10.1371/journal.pone.0011603.g007
Figure 8. Furan-metoticas kill proliferating cells with an efficiency equaling that of established antitubulin drugs. Viability analysis of
hTERT RPE-1 control cells and two adenocarcinoma cell lines following treatment with compound A8 (1–1000 nmol/l); nocodazole and colchicine
acted as positive controls.
doi:10.1371/journal.pone.0011603.g008
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Quantitative comparisons of drug effects on tubulin assembly were
also examined in 0.8 M glutamate with a 15 min drug-tubulin
preincubation prior to the addition of GTP [14]. Tubulin
assembly was monitored for 20 min at 30uC in Beckman
DU7400/7500 spectrophotometers, and the compound concen-
tration inhibiting tubulin assembly by 50% was determined.
[
3H]colchicine competition experiments
Tubulin binding of [
3H]colchicine was measured by the DEAE-
cellulose filter method [20]. Reaction mixtures contained
1.0 mmol/l ab-tubulin, 1.0 mol/l monosodium glutamate,
0.1 mol/l glucose-1-phosphate, 1.0 mmol/l MgCl2, 1.0 mmol/l
GTP, 0.5 mg/ml BSA, 5% DMSO, 5 mmol/l [
3H]colchicine, and
inhibitor at 1, 5, 20 or 50 mmol/l. These reaction conditions
strongly stabilize the colchicine-binding activity of tubulin [21].
Compound-based depolymerization of taxol-stabilized
MTs
Taxol-stabilized MTs were prepared and diluted as described
for the Ndc80
488 binding experiments. Varying compound
concentrations in 10 ml of DMSO were added to 490 ml of diluted
MTs at 37uC. Following incubation (30 min, 37uC), 450 ml of each
mixture was centrifuged (10 min; 30,000 rpm; 37uC) in a Beck-
man Optima TLX centrifuge (TLA120.1 rotor). Pellets were
dissolved in 25 ml of 8 mol/l urea, and the protein content of 20 ml
was compared with that from pellets formed without compound.
Viability analysis of adenocarcinoma cells
Viability analysis in the presence of antitubulin drugs was
performed on hTERT RPE-1 (ATCC), HCT-116 (ATCC), and
A2780 (EACC) cell lines. Cell lines were authenticated by PCR
[22]. Absence of eight commonly encountered mycoplasma
species was confirmed by PCR [23]. Experiments were performed
with freshly thawed cells, which were seeded in 96-well
MICROTEST tissue culture plates (Falcon) at ,500 cells/well
and grown at 37uC. After 6 h, nocodazole, colchicine or
compound A8 were added (1–1000 nmol/l). The cells were
incubated for 3 d at 37uC and then assayed for viability (CellTiter
96 Assay, Promega).
Immunofluorescence (IF) imaging
G1/S synchronization with 2.5 mmol/l thymidine was carried
out for 16 h. IF imaging (Leica TCS SP2 confocal microscope)
was performed on cells fixed with 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100 and treated with 4%
BSA. The cells were incubated with appropriate antibodies diluted
in 4% BSA in PBS. Primary antibodies used in IF imaging were
mouse monoclonal antiNdc80 antibody (1:1000, Genetex Clone
9G3.23), CREST serum (1:50, Antibodies Incorporation) and
mouse monoclonal anti-a-tubulin antibody (1:2000, Sigma-
Aldrich Clone B512). Secondary antibodies used were Alexa
Fluor 488 (1:150), Cy3 (1:400) and Cy5 (1:50) (Jackson
Immunoresearch).
Supporting Information
Figure S1 Fragments used to search chemical libraries for
compound analogues. Fragments of compound B (6-Furan-2-
yl-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylic acid
tetrahydro-furan-2-ylmethyl ester), encircled in blue and red, that
were used in the computer-assisted search of compound libraries.
Found at: doi:10.1371/journal.pone.0011603.s001 (1.46 MB TIF)
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